News
-
RDD Online and Aptar Pharma have announced that registration is now open for Respiratory Drug Delivery (RDD) Europe 2015, to be held May 5-8, 2015 in Antibes, France. This will be the 10th anniversary of… Read more . . .
-
Lightlake Therapeutics has announced that it has begun a new trial of its intranasal naloxone for the reversal of opioid overdose. According to the company, it plans to file a New Drug Application with the… Read more . . .
-
PulmoFlow has announced that the FDA has approved its NDA for Kitabis Pak, generic tobramycin inhalation solution packaged with a PARI LC PLUS nebulizer, for the treatment P. aeruginosa infections in cystic fibrosis patients. PARI… Read more . . .
-
Meda Pharmaceuticals and Cipla have filed suit against Apotex in the Delaware Federal District Court, claiming that Apotex’s submission of an ANDA for a generic version of Dymista azelastine HCl/fluticasone propionate nasal spray violates patents… Read more . . .
-
Avanir Pharmaceuticals, which just received a complete response letter from the FDA for its AVP-825 intranasal sumatriptan powder, has announced that it will be acquired by Otsuka Pharmaceutical for approximately $3.5 billion. Avanir will become… Read more . . .
-
Skyepharma has announced that Mundipharma has launched the Flutiform fluticasone/formoterol MDI for the treatment of asthma in Spain, triggering a milestone payment of €2.0 million. In addition, Mundipharma marketing partner Zambon Italia has now launched… Read more . . .
-
According to Avanir Pharmaceuticals, it has received a Complete Response Letter (CRL) from the FDA regarding its New Drug Application (NDA) for AVP-825 intranasal sumatriptan for the treatment of migraine. The company had recently warned… Read more . . .
-
Respiratory drug developer Verona Pharma has named former Galenica CEO David Ebsworth as Non-Executive Chairman of the Board of Directors. Ebsworth succeeds Clive Page, who founded the company in 2006. The company’s lead product, RPL554,… Read more . . .
-
According to Bayer, its Amikacin Inhale inhalation solution and its ciprofloxacin DPI have both been granted qualified infectious disease product (QIDP) designation by the FDA. Both products are currently in Phase 3 development. Bayer HealthCare… Read more . . .
-
Milestone Pharmaceuticals has announced that a Phase 1 clinical trial of an intranasal formulation of its MSP-2017 calcium channel antagonist for possible treatment of paroxysmal supraventricular tachycardia (PSVT) showed that the drug has a rapid… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.